Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.

You may also be interested in...



BMS Jumps Ahead With LAG-3 Melanoma Data

LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.

Keytruda's Broad Confirmatory Trials Suggest Evolution Of US FDA’s Accelerated Approval Model

FDA’s most recent accelerated approvals for Merck’s Keytruda call for confirmatory trials in a broader patient population than the approved indications, in the latest example of FDA’s growing comfort with multi-purpose confirmatory trials in the PD-1/PD-L1 inhibitor space.

Bristol Taking A Cautious Approach To Triple Immuno-Oncology Combos

The company is starting to explore triple immuno-oncology combinations, Head of Oncology-Global Clinical Research Jean Viallet said, but IO development is mainly focused on expanding the firm's existing double combination, Opdivo and Yervoy, to earlier treatment and new tumors.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel